Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Clinical Drug Investigation
|
May 14, 2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni, et al.
Psychopharmacology
|
February 7, 2021
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
Ramakrishna Nirogi, Vijay Benade, Saivishal Daripelli, et al.
Archiv Der Pharmazie
|
December 17, 2024
New 7-hydroxycoumarin acetamide derivatives as human carbonic anhydrase IX and XII inhibitors: Design, synthesis, biological evaluation and molecular docking studies
Sarvan Maddipatla, Bulti Bakchi, Mayura Anil Shinde, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 6, 2022
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study
Ramakrishna Nirogi, John Ieni, Vinod Kumar Goyal, et al.
Journal of Medicinal Chemistry
|
September 26, 2012
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists
Ramakrishna Nirogi, Anil Shinde, Anand Daulatabad, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Vijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
International Journal of Geriatric Psychiatry
|
September 28, 2022
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
Ramakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, et al.
Sleep Medicine
|
November 6, 2024
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
Ramakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Clinical Drug Investigation
|
May 14, 2020
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
Ramakrishna Nirogi, Koteshwara Mudigonda, Gopinadh Bhyrapuneni, et al.
Psychopharmacology
|
February 7, 2021
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
Ramakrishna Nirogi, Vijay Benade, Saivishal Daripelli, et al.
Archiv Der Pharmazie
|
December 17, 2024
New 7-hydroxycoumarin acetamide derivatives as human carbonic anhydrase IX and XII inhibitors: Design, synthesis, biological evaluation and molecular docking studies
Sarvan Maddipatla, Bulti Bakchi, Mayura Anil Shinde, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 6, 2022
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study
Ramakrishna Nirogi, John Ieni, Vinod Kumar Goyal, et al.
Journal of Medicinal Chemistry
|
September 26, 2012
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists
Ramakrishna Nirogi, Anil Shinde, Anand Daulatabad, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Vijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
International Journal of Geriatric Psychiatry
|
September 28, 2022
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
Ramakrishna Nirogi, Pradeep Jayarajan, Vijay Benade, et al.
Sleep Medicine
|
November 6, 2024
Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
Ramakrishna Nirogi, Anil Shinde, Vinod Kumar Goyal, et al.
Page
of 4